Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00042562 · ClinicalTrials.gov registry record · Phase 3
Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00042562 is a Phase 3 study that has completed, run by Eli Lilly and Company.
The verdict
NCT00042562, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purposes of this study are to determine: The safety of duloxetine and any side effects that might be associated with it. Whether duloxetine can help patients with major depression. The safety associated with switching from a medication you may be taking for depression to taking duloxetine. It is possible that information collected during this study will be analyzed by the sponsor in the future to evaluate duloxetine for other possible uses or for other medical or scientific purposes other than those currently proposed.
Interventions
- DRUG duloxetine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-12 |
| Est. Completion | 2003-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00042562
The ClinicalTrials.gov registry entry for NCT00042562 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which duloxetine is the first listed.
NCT00042562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00042562 about?
NCT00042562 is a clinical study titled "Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression". The purposes of this study are to determine: The safety of duloxetine and any side effects that might be associated with it. Whether duloxetine can help patients with major depression. The safety associated with switching from a medication you may be taking for depression to taking duloxetine. I...
What is the current status of trial NCT00042562?
This trial is currently completed. It is a Phase 3 study. The study started on 2002-12. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00042562?
The interventions under investigation include: duloxetine (DRUG).
Who is sponsoring clinical trial NCT00042562?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.